BioCryst Pharmaceuticals
BCRX
$4.16
Share price
0.00%
Change (1 day)
-44.75%
Change (1 year)
Categories
P/S ratio for BioCryst Pharmaceuticals (BCRX)
P/S ratio as of April 2024 (TTM): 2.59
According to BioCryst Pharmaceuticals 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.59078. At the end of 2023 the company had a P/S ratio of 3.70.
P/S ratio history for BioCryst Pharmaceuticals from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 3.70 | -53.16% |
| 2022 | 7.90 | -50.16% |
| 2021 | 15.9 | -78.53% |
| 2020 | 73.8 | 578.44% |
| 2019 | 10.9 | -74.69% |
| 2018 | 43.0 | 124.18% |
| 2017 | 19.2 | 8.28% |
| 2016 | 17.7 | 12.94% |
| 2015 | 15.7 | -75.6% |
| 2014 | 64.3 | 148.13% |
| 2013 | 25.9 | 842.78% |
| 2012 | 2.75 | -51.66% |
| 2011 | 5.69 | 52.58% |
| 2010 | 3.73 | -2.01% |
| 2009 | 3.80 | 310.36% |
| 2008 | 0.9267 | -71.87% |
| 2007 | 3.29 | -93.95% |
| 2006 | 54.4 | -98.29% |
| 2005 | > 1000 | -77.51% |
| 2004 | > 1000 | 18759.03% |
| 2003 | 74.9 | 684.31% |
| 2002 | 9.55 | 52.86% |
| 2001 | 6.25 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | 3.01 | 16.12% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.22 | -14.21% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | 9.81 | 278.47% | 🇺🇸 USA |
 Repligen
RGEN | 14.6 | 462.60% | 🇺🇸 USA |
 Novavax NVAX | 0.8249 | -68.16% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 346 | 13,273.81% | 🇺🇸 USA |
 NanoViricides NNVC | N/A | N/A | 🇺🇸 USA |
 Cel-Sci
CVM | N/A | N/A | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.0983 | -96.21% | 🇺🇸 USA |